{Reference Type}: Journal Article
{Title}: Effects of acetazolamide on linear growth in children with pseudotumor cerebri syndrome.
{Author}: Sheldon CA;Reggie SN;Paley GL;McCormack SE;Liu GT;
{Journal}: Front Ophthalmol (Lausanne)
{Volume}: 2
{Issue}: 0
{Year}: 2022
暂无{DOI}: 10.3389/fopht.2022.1042529
{Abstract}: <B>UNASSIGNED: </B>While oral acetazolamide is a cornerstone of management of adult and pediatric PTCS, previous studies have suggested that acetazolamide used in children with other conditions may influence growth.<BR><B>UNASSIGNED: </B>Retrospective chart review involving a single tertiary medical center. Thirty-four children with definite or probable PTCS were identified. Analysis was restricted to individuals from whom anthropometric data were available before and during acetazolamide treatment (n=22).<BR><B>UNASSIGNED: </B>Half of individuals (n=11/22) showed a decline in BMI Z-scores. Sixty-three percent (n=14/22) showed a decrease in height Z-scores during treatment with acetazolamide; in 6 of these 14 children who had complete data, 3 showed at least a partial recovery of height Z-scores after discontinuation of acetazolamide.<BR><B>UNASSIGNED: </B>Acetazolamide may be associated with growth suppression in some children treated for pediatric PTCS. In some cases, the growth suppression appears to reverse once the acetazolamide is stopped.